Patents by Inventor Shizuo Shiozaki
Shizuo Shiozaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9238033Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.Type: GrantFiled: April 24, 2013Date of Patent: January 19, 2016Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi Kase, Minoru Kobayashi, Shizuo Shiozaki, Akihisa Mori, Naoki Seno
-
Patent number: 8592420Abstract: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.Type: GrantFiled: April 16, 2012Date of Patent: November 26, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Naoki Seno, Shizuo Shiozaki, Minoru Kobayashi, Junya Kase
-
Publication number: 20130237526Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.Type: ApplicationFiled: April 24, 2013Publication date: September 12, 2013Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Minoru Kobayashi, Shizuo Shiozaki, Akihisa Mori, Naoki Seno
-
Patent number: 8440678Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.Type: GrantFiled: September 16, 2011Date of Patent: May 14, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Minoru Kobayashi, Shizuo Shiozaki, Akihisa Mori, Naoki Seno
-
Publication number: 20120232089Abstract: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.Type: ApplicationFiled: April 16, 2012Publication date: September 13, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi Kase, Naoki Seno, Shizuo Shiozaki, Minoru Kobayashi, Junya Kase
-
Patent number: 8202869Abstract: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.Type: GrantFiled: June 10, 2004Date of Patent: June 19, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Naoki Seno, Shizuo Shiozaki, Minoru Kobayashi, Junya Kase
-
Publication number: 20120010225Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.Type: ApplicationFiled: September 16, 2011Publication date: January 12, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi Kase, Minoru Kobayashi, Shizuo Shiozaki, Akihisa Mori, Naoki Seno
-
Patent number: 8034820Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.Type: GrantFiled: July 22, 2004Date of Patent: October 11, 2011Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiroshi Kase, Minoru Kobayashi, Shizuo Shiozaki, Akihisa Mori, Naoki Seno
-
Patent number: 7851478Abstract: For example, an agent for preventing and/or treating movement disorder comprising, as an active ingredient, a triazolopyrimidine derivative having an adenosine A2A receptor antagonistic action, which is represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, R2 represents a hydrogen atom, or the like, R3 represents —WR4, or the like, and Q1 represents a hydrogen atom or 3,4-dimethoxybenzyl), or a pharmaceutically acceptable salt thereof, and the like are provided.Type: GrantFiled: June 7, 2006Date of Patent: December 14, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Takako Kadowaki, Minoru Kobayashi, Shizuo Shiozaki, Naoki Seno
-
Publication number: 20090105277Abstract: For example, an agent for preventing and/or treating movement disorder comprising, as an active ingredient, a triazolopyrimidine derivative having an adenosine A2A receptor antagonistic action, which is represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, R2 represents a hydrogen atom, or the like, R3 represents —WR4, or the like, and Q1 represents a hydrogen atom or 3,4-dimethoxybenzyl), or a pharmaceutically acceptable salt thereof, and the like are provided.Type: ApplicationFiled: June 7, 2006Publication date: April 23, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Takako Kadowaki, Minoru Kobayashi, Shizuo Shiozaki, Naoki Seno
-
Publication number: 20090023755Abstract: The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like.Type: ApplicationFiled: September 29, 2008Publication date: January 22, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Shizuo Shiozaki, Junichi Shimada, Hiroshi Kase, Mayumi Shindo
-
Publication number: 20070149555Abstract: A prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain comprising as an active ingredient a compound having an adenosine A2A receptor antagonistic action, for example, represented by the following formula (I) (wherein R1, R2 and R3 are the same or different, each representing a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R4 represents cycloalkyl, —(CH2)n—R5 or the following formula (II); and X1 and X2 are the same or different, each representing an oxygen atom or a sulfur atom) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 30, 2005Publication date: June 28, 2007Applicant: Kyowa Hakko Kogyo Co., LtdInventors: Hiroshi Kase, Isami Takahashi, Shunji Kunori, Minoru Kobayashi, Shizuo Shiozaki, Shiro Shirakura
-
Publication number: 20070078148Abstract: (wherein R1, R2 and R3 are the same or different, and represent a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R4 represents cycloalkyl, —(CH2)n—R5 or a group represented by the above formula (II); and X1 and X2 are the same or different, and represent an oxygen atom or a sulfur atom) The present invention provides, for example, agents for preventing and/or treating higher brain dysfunction comprising, as an active ingredient, a xanthine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 9, 2004Publication date: April 5, 2007Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiroshi Kase, Yutaka Nakagawa, Shizuo Shiozaki, Minoru Kobayashi, Shinichiro Toki, Naoki Seno, Ken Ikeda
-
Publication number: 20060281770Abstract: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.Type: ApplicationFiled: June 10, 2004Publication date: December 14, 2006Applicant: Kyowa Hakko Kogyo Co. LtdInventors: Hiroshi Kase, Naoki Seno, Shizuo Shiozaki, Minoru Kobayashi, Junya Kase
-
Publication number: 20060241102Abstract: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.Type: ApplicationFiled: July 22, 2004Publication date: October 26, 2006Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiroshi Kase, Minoru Kobayashi, Shizuo Shiozaki, Akihisa Mori, Naoki Seno
-
Publication number: 20060069107Abstract: The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like.Type: ApplicationFiled: December 24, 2003Publication date: March 30, 2006Applicant: Kyowa Hakko Kogyo Co. Ltd.Inventors: Shizuo Shiozaki, Junichi Shimada, Hiroshi Kase, Mayumi Shindo
-
Publication number: 20060058320Abstract: The present invention provides [1,2,4]triazolo[1,5-c]pyrimidine derivatives or pharmaceutically acceptable salts thereof which have adenosine A2A receptor antagonism and are useful for treating and/or preventing a disease induced by hyperactivity of an adenosine A2A receptor, the derivatives being represented by formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents a hydrogen atom, halogen, lower alkyl, lower alkanoyl, aroyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents lower alkyl, lower cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; and Q represents a hydrogen atom or 3,4-dimethoxybenzyl).Type: ApplicationFiled: September 24, 2003Publication date: March 16, 2006Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kyoichiro Iida, Takamasa Sugita, Shizuo Shiozaki, Tomoyuki Kanda, Yoshihisa Kuwana, Junichi Shimada
-
Patent number: 6545000Abstract: The present invention relates to [1,2,4]triazolo[1,5-c]pyrimidine compounds represented by formula (I): wherein na and nb independently represent an integer of 0 to 4 and Q represents a hydrogen atom or 3,4-dimethoxybenzyl, or salts thereof exhibit activity as adenosine A2A receptor antagonists.Type: GrantFiled: March 22, 2001Date of Patent: April 8, 2003Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Junichi Shimada, Hironori Imma, Naoto Osakada, Shizuo Shiozaki, Tomoyuki Kanda, Yoshihisa Kuwana
-
Patent number: 6222035Abstract: [1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A2A receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A2A receptors (for example, Parkinson's disease or senile dementia): wherein R1 represents substituted or unsubstituted aryl, or the like; R2 represents hydrogen, halogen, lower alkyl, substituted or unsubstituted aryl, or the like; R3 represents hydrogen, halogen, XR10 (wherein X represents O or S; and R10 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aralkyl, lower alkyl, or hydroxy lower alkyl), or the like; and Q represents hydrogen or 3,4-dimethoxybenzyl.Type: GrantFiled: September 23, 1999Date of Patent: April 24, 2001Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiroshi Tsumuki, Junichi Shimada, Hironori Imma, Akiko Nakamura, Hiromi Nonaka, Shizuo Shiozaki, Shunji Ichikawa, Tomoyuki Kanda, Yoshihisa Kuwana, Michio Ichimura, Fumio Suzuki
-
Patent number: 5789407Abstract: The present invention relates to an antidepressant containing as an active ingredient a triazine derivative or a pharmaceutically acceptable salt thereof, the derivative being represented by the following Formula (I): ##STR1## in which, R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower alkanoyl; R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic group; R.sup.3 represents a substituted or unsubstituted heterocyclic group; X represents a single bond, O, S, S(O), S(O).sub.2, or NR.sup.4 (in which R.sup.4 represents hydrogen, or substituted or unsubstituted lower alkyl; or R.sup.2 and NR.sup.4 are combined to form a substituted or unsubstituted 4 to 6-membered saturated heterocyclic group); and A represents N or CR.sup.5 (in which R.Type: GrantFiled: April 25, 1995Date of Patent: August 4, 1998Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Fumio Suzuki, Nobuaki Koike, Junichi Shimada, Shigeto Kitamura, Shunji Ichikawa, Joji Nakamura, Shizuo Shiozaki